Company intelligence / Profile preview

Azadyne

London, United Kingdom

Ownership: Private
Development stage: Other

Overview

Azadyne’s approach has shown striking efficacy in pre-clinical studies via the TGT enzyme pathway against a range of autoimmune diseases without broad immune suppression. The technology selectively controls natural regulatory pathways to modify specific pathogenic immune populations, offering therapeutic benefit across multiple models and human samples. Effects are seen on multiple components of the autoimmune response without causing general immunosuppression. Multiple chemical series with oral bioavailability have been identified.

Therapeutic areas: ImmunologyNeurology
Modalities: Small moleculeRNA therapyBiologic
Industry: Biotech

Drug pipeline

3 assets

MS-19-16

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Rosalind Franklin Instituteo2h discovery

Beyond the preview

Go deeper on Azadyne.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Azadyne.

Explore the full profile